Paradigm Biopharmaceuticals Ltd has released a press release.
Clarification of recent analyst report on Patent Protection
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- S&P DJI Announces March 2022 Quarterly Rebalance
- Paradigm 1HY22 Key Activity Highlights
- Paradigm treats first subjects in phase 3 trial of Zilosul
- PAR reports postive topline results in heart failure model
- Preliminary Results from Phase 2 MPS I Study
Later from Paradigm Biopharmaceuticals
- FDA Grants Paradigm Fast Track Designation For OA
- Paradigm Doses First US Subjects under Phase 3 trial
- Paradigm Appoints Experienced US-Based CEO
- Paradigm Receives $8.2m R&D Tax Incentive Refund
- Paradigm Reports Australian Patent Acceptance
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals